RayKnowChina Research Map
Shortlist

Sun Yat-sen University

中山大学

GuangzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
23.4%Leads about 1 in 4 of China's research papers on NPC

Led 555 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
85
Research papers it led
555
Trials it led
243
Share of China's trials
40.8%
Share of the world's papers
17.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Papers it led5
  1. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 stu2025Lancet (London, England)RCT
  2. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.2025JAMA oncologyRCTFree full text
  3. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.2025BMJ (Clinical research ed.)RCTFree full text
  4. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.2025JAMARCTFree full text
  5. Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
Trials on ClinicalTrials.gov6
  1. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Lead sponsorPhase 2Start 2026-07
  2. Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal CarcinomaRecruitingNCT07567742Lead sponsorPhase 2Start 2026-05
  3. GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Lead sponsorPhase 3Start 2026-05
  4. Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Lead sponsorPhase 1Start 2026-05
  5. Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With ImmunotherapyRecruitingNCT07496190Lead sponsorPhase 2Start 2026-02
  6. A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT07392320Lead sponsorPhase 2Start 2026-02

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
6.1%Leads about 1 in 16 of China's research papers on ESCC

Led 179 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
15
Research papers it led
179
Trials it led
48
Share of China's trials
8.5%
Share of the world's papers
4.1%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025
ThemesNeoadjuvant & combined treatmentMolecular markers & genomicsRadiotherapy
Papers it led5
  1. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.2022Cancer cellRCT
  2. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.2021JAMARCTFree full text
  3. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.2021JAMA surgeryRCTFree full text
  4. Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial.2025The oncologistRCTFree full text
  5. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.2024Med (New York, N.Y.)RCT
Trials on ClinicalTrials.gov6
  1. Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT07595770Lead sponsorPhase 2Start 2026-05
  2. An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07709533Lead sponsorPhase 2Start 2026-07
  3. Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07638436Lead sponsorPhase 2Start 2026-06
  4. A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingNCT07863141Lead sponsorPhase 2Start 2026-10
  5. Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Lead sponsorPhase 2Start 2026-08
  6. Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Lead sponsorPhase 2Start 2026-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
5.5%Leads about 1 in 18 of China's research papers on HCC

Led 820 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
52
Research papers it led
820
Trials it led
232
Share of China's trials
15.8%
Share of the world's papers
2.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Papers it led5
  1. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  2. Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.2024Cancer communications (London, England)RCTFree full text
  3. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.2024JAMA oncologyRCTFree full text
  4. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.2024JAMA surgeryRCTFree full text
  5. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
Trials on ClinicalTrials.gov6
  1. Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaRecruitingNCT07324824Lead sponsorPhase 2Start 2026-01
  2. Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingNCT07870772Lead sponsorPhase 2Start 2026-10
  3. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNot yet recruitingNCT07880106Lead sponsorStart 2026-10
  4. HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)RecruitingNCT07594340Lead sponsorPhase 3Start 2026-05
  5. TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCCRecruitingNCT07658833Lead sponsorStart 2026-07
  6. SBRT Versus Surgical Resection for Small HCCRecruitingNCT07381660Lead sponsorPhase 3Start 2026-03

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.9%Leads about 1 in 35 of China's research papers on Stomach cancer

Led 283 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
14
Research papers it led
283
Trials it led
61
Share of China's trials
4.2%
Share of the world's papers
1.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 3320242025: 002025
ThemesPeritoneal spread & advanced diseaseChemotherapy & combined treatmentImaging & AI
Papers it led5
  1. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.2024Nature medicineRCT
  2. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.2024BMJ (Clinical research ed.)RCT
  3. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.2024Nature medicineRCT
  4. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.2023Nature medicineRCTFree full text
  5. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.2021JAMA network openRCTFree full text
Trials on ClinicalTrials.gov6
  1. Large Language Models Assist in Tumor MDTRecruitingNCT07504367Lead sponsorN/AStart 2026-01
  2. Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Lead sponsorPhase 2Start 2026-08
  3. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNot yet recruitingNCT07880106Lead sponsorStart 2026-10
  4. A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingNCT07507526Lead sponsorPhase 2Start 2026-04
  5. Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric CancerNot yet recruitingNCT06365008Lead sponsorPhase 2Start 2026-06
  6. Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Lead sponsorPhase 1/Phase 2Start 2025-03

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
5.8%Leads about 1 in 17 of China's research papers on Hepatoblastoma ▲ from 1.2%

Led 9 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
1
Research papers it led
9
Trials it led
2
Share of China's trials
20.0%
Share of the world's papers
2.0%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
9.3%Leads about 1 in 11 of China's research papers on Retinoblastoma ▲ from 7.2%

Led 28 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
7
Share of China's trials
53.8%
Share of the world's papers
2.5%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
3.3%Leads about 1 in 30 of China's research papers on Osteosarcoma ▲ from 2.1%

Led 75 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
1
Research papers it led
75
Trials it led
5
Share of China's trials
8.6%
Share of the world's papers
1.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Papers it led5
  1. Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma.2025Journal for immunotherapy of cancer
  2. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes.2021Signal transduction and targeted therapy
  3. A prediction model of pulmonary metastasis risk in pediatric patients with stage IIB osteosarcoma in the long bone of extremities.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study.2025Drug design, development and therapy
  5. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.2024Cancer medicine
Trials on ClinicalTrials.gov6
  1. Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaRecruitingNCT07648069Lead sponsorPhase 1Start 2024-09
  2. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  3. Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaRecruitingNCT07602049Lead sponsorPhase 2Start 2024-11
  4. Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Lead sponsorPhase 2Start 2021-12
  5. Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of OsteosarcomaStatus unknownNCT04294511Lead sponsorPhase 2Start 2019-12
  6. Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat OsteosarcomaStatus unknownNCT01669369Lead sponsorPhase 4Start 2013-01

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
3.8%Leads about 1 in 26 of China's research papers on Gastrointestinal stromal tumour

Led 20 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
2
Research papers it led
20
Trials it led
6
Share of China's trials
8.1%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
Papers it led5
  1. Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research.2025Signal transduction and targeted therapy
  2. Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study.2025Future oncology (London, England)
  3. Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.2024Current treatment options in oncology
  4. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.2024European radiology
  5. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.2023Advances in therapy
Trials on ClinicalTrials.gov6
  1. A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal TumorsRecruitingNCT05464875Lead sponsorStart 2022-07
  2. Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRARecruitingNCT05461664Lead sponsorStart 2022-07
  3. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  4. A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Study sitePhase 3Start 2024-11
  5. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  6. The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTsStatus unknownNCT06431451Lead sponsorStart 2024-06

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.4%Leads about 1 in 71 of China's research papers on Neuroblastoma ▼ from 3.2%

Led 16 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
6
Research papers it led
16
Trials it led
9
Share of China's trials
21.4%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Sun Yat-sen Memorial Hospital8
  2. Sun Yat-sen University Cancer Center7
  3. Third Affiliated Hospital of Sun Yat-sen University1
  4. Eighth Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.2024BMC cancer
  2. Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.2021Oncology research
  3. SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.2025Journal of translational medicine
  4. Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas.2024Cancer reports (Hoboken, N.J.)
  5. SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesis.2024Oncogene
Trials on ClinicalTrials.gov6
  1. Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Lead sponsorPhase 1Start 2026-05
  2. Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaRecruitingNCT06933394Lead sponsorPhase 2Start 2025-05
  3. Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.RecruitingNCT06836505Lead sponsorPhase 1/Phase 2Start 2024-12
  4. Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.RecruitingNCT06631391Lead sponsorPhase 1Start 2024-11
  5. Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaRecruitingNCT06013618Lead sponsorPhase 2Start 2023-06
  6. Serial ctDNA and Molecular Residual Disease Monitoring in NeuroblastomaRecruitingNCT07516678Lead sponsorStart 2022-01

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
3.7%Leads about 1 in 27 of China's research papers on Ewing sarcoma ▲ from 1.2%

Led 6 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
1
Research papers it led
6
Trials it led
2
Share of China's trials
12.5%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Sun Yat-sen University Cancer Center3
  2. Sun Yat-sen Memorial Hospital2
  3. Eighth Affiliated Hospital of Sun Yat-sen University1
  4. First Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.9%Leads about 1 in 34 of China's research papers on Myeloma

Led 49 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
49
Trials it led
6
Share of China's trials
1.2%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025
ThemesDiagnosis, MRD & riskStem cell transplantDrug combinations
Papers it led5
  1. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCTFree full text
  2. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.2022Integrative cancer therapiesRCTFree full text
  3. Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C.2021Cancer communications (London, England)Free full text
  4. Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma.2026Archives of medical research
  5. Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  2. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  3. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  4. Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT07369895Study sitePhase 1Start 2025-10
  5. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  6. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
4.4%Leads about 1 in 23 of China's research papers on B-ALL ▲ from 1.0%

Led 10 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
10
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025
ThemesChildrenPhiladelphia chromosome & geneticsMRD & relapse
Papers it led5
  1. Dysregulated arginine metabolism in precursor B-cell acute lymphoblastic leukemia in children: a metabolomic study.2024BMC pediatricsFree full text
  2. Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.2024European journal of haematology
  3. The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia.2024BMC medical genomicsFree full text
  4. Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children.2023Frontiers in immunologyFree full text
  5. Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.2023Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineRecruitingNCT06060782Lead sponsorPhase 1Start 2024-03
  2. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  3. Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06580301Study sitePhase 1/Phase 2Start 2024-09
  4. Monitoring Minimal Residual Disease(MRD)in Pediatric B-acute Lymphoblastic LeukemiaStatus unknownNCT04977895Lead sponsorStart 2021-01
  5. A Study of Ponsegromab in People With Heart FailureTerminatedNCT05492500Study sitePhase 2Start 2022-09
  6. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.7%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▼ from 1.7%

Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025
ThemesChildren

Hospitals counted here

  1. Sixth Affiliated Hospital of Sun Yat-sen University Counted in the group total1
  2. Sun Yat-sen Memorial Hospital Counted in the group total1
  3. Third Affiliated Hospital of Sun Yat-sen University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
2.3%Leads about 1 in 44 of China's research papers on HLH ▼ from 3.7%

Led 9 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025
ThemesChildrenDiagnosis & prognosisTreatment regimens

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
4.5%Leads about 1 in 22 of China's research papers on Beta thalassaemia ▼ from 10.3%

Led 14 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
2
Share of China's trials
4.3%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
Papers it led5
  1. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  2. Clinical patterns of thalidomide in the treatment of transfusion-dependent β-thalassaemia in children: a prospective single-arm study in China.2025Annals of medicine
  3. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  4. A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.2024Stem cell research & therapy
  5. Technically feasible solutions to challenges in preimplantation genetic testing for thalassemia: experiences of multiple centers between 2019 and 2022.2024Journal of assisted reproduction and genetics
Trials on ClinicalTrials.gov5
  1. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  2. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  3. Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing FactorsStatus unknownNCT06026839Lead sponsorStart 2023-10
  4. The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world StudyStatus unknownNCT05462548Lead sponsorPhase 4Start 2022-07
  5. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruitingNCT05577312Study sitePhase 1/Phase 2Start 2022-11

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.1%Leads about 1 in 91 of China's research papers on Haemophilia A

Led 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Seventh Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
9.5%Leads about 1 in 11 of China's research papers on NMOSD ▼ from 13.3%

Led 46 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
3
Research papers it led
46
Trials it led
4
Share of China's trials
5.1%
Share of the world's papers
2.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesAntibodies & diagnosisAcute attack treatmentImaging

Hospitals counted here

  1. Third Affiliated Hospital of Sun Yat-sen University39
  2. Zhongshan Ophthalmic Center4
  3. First Affiliated Hospital of Sun Yat-sen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.2023JAMA neurologyFree full text
  2. Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.2026Multiple sclerosis and related disorders
  3. Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks.2025British journal of clinical pharmacology
  4. Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.2025Journal of neurology
  5. Impact of Treatment Delay and Prognostic Factors in Acute Myelitis of Neuromyelitis Optica Spectrum Disease.2025Brain and behaviorFree full text
Trials on ClinicalTrials.gov6
  1. Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum DisorderRecruitingNCT06763848Lead sponsorN/AStart 2025-04
  2. Cohort Study on Neuroimmune Diseases in the Reproductive AgeRecruitingNCT07653984Lead sponsorStart 2024-04
  3. Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating DiseasesRecruitingNCT06541626Lead sponsorStart 2024-01
  4. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  5. Treatment Response Among Chinese Neuromyelitis Optica Spectrum DisordersStatus unknownNCT04101058Lead sponsorStart 2019-01
  6. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
2.4%Leads about 1 in 41 of China's research papers on IgG4-RD

Led 6 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025
ThemesDiagnosis & look-alikesPancreas & bile ductsLung & chest

Hospitals counted here

  1. Sun Yat-sen Memorial Hospital4
  2. Fifth Affiliated Hospital of Sun Yat-sen University Counted in the group total1
  3. Third Affiliated Hospital of Sun Yat-sen University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
5.6%Leads about 1 in 18 of China's research papers on Myasthenia gravis

Led 28 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
4
Share of China's trials
4.3%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesThymus & thymectomyStandard immunotherapyEye-only (ocular) myasthenia

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University28

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Preoperative respiratory muscle training combined with aerobic exercise improves respiratory vital capacity and daily life activity following surgical treatment for myasthenia gravis.2023Journal of cardiothoracic surgeryRCTFree full text
  2. Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.2026Annals of neurology
  3. Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report.2025VirulenceFree full text
  4. Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study.2025International immunopharmacology
  5. Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit.2025BMC neurologyFree full text
Trials on ClinicalTrials.gov6
  1. Cohort Study on Neuroimmune Diseases in the Reproductive AgeRecruitingNCT07653984Lead sponsorStart 2024-04
  2. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05332587Lead sponsorPhase 3Start 2020-08
  5. Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia GravisStatus unknownNCT03597373Lead sponsorStart 2017-01
  6. The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyCompletedNCT01727193Lead sponsorPhase 3Start 2012-09

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.0%Leads about 1 in 51 of China's research papers on Moyamoya

Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesRevascularisation surgeryImaging & blood flowStroke & bleeding outcomes

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University4
  2. Third Affiliated Hospital of Sun Yat-sen University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
3.5%Leads about 1 in 29 of China's research papers on Wilson disease ▼ from 7.3%

Led 7 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
1
Share of China's trials
6.2%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025
ThemesGenetics (ATP7B)Brain & movement symptomsTreatment (chelation, zinc)

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University6
  2. Zhongshan Ophthalmic Center Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
6.1%Leads about 1 in 16 of China's research papers on Biliary atresia

Led 13 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.7%
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 1120242025: 002025
ThemesScreening & diagnosisDisease mechanismsLong-term outcomes

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University12
  2. Third Affiliated Hospital of Sun Yat-sen University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
9.1%Leads about 1 in 11 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 7.3%

Led 24 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
24
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
3.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Hospitals counted here

  1. Third Affiliated Hospital of Sun Yat-sen University22
  2. First Affiliated Hospital of Sun Yat-sen University2
  3. Seventh Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis New since 2021

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Third Affiliated Hospital of Sun Yat-sen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
2.0%Leads about 1 in 51 of China's research papers on Hepatic echinococcosis ▲ from 1.1%

Led 3 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
50.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Sun Yat-sen Memorial Hospital1
  2. Fifth Affiliated Hospital of Sun Yat-sen University1
  3. First Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.7%Leads about 1 in 58 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 17 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.3%Leads about 1 in 78 of China's research papers on Amyotrophic lateral sclerosis ▲ from 0.5%

Led 10 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
7.3%Leads about 1 in 14 of China's research papers on Spinal muscular atrophy New since 2021

Led 4 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
3.3%Leads about 1 in 30 of China's research papers on Duchenne muscular dystrophy ▼ from 5.1%

Led 7 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University5
  2. Seventh Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
5.3%Leads about 1 in 19 of China's research papers on Behçet disease ▲ from 2.9%

Led 13 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
1
Share of China's trials
5.9%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025

Hospitals counted here

  1. Zhongshan Ophthalmic Center7
  2. First Affiliated Hospital of Sun Yat-sen University4
  3. Sun Yat-sen Memorial Hospital1
  4. Sixth Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
4.9%Leads about 1 in 20 of China's research papers on IgA nephropathy ▼ from 7.7%

Led 36 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
2
Research papers it led
36
Trials it led
8
Share of China's trials
6.8%
Share of the world's papers
2.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.0%Leads about 1 in 100 of China's research papers on Primary biliary cholangitis ▼ from 2.0%

Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
2
Share of China's trials
4.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Third Affiliated Hospital of Sun Yat-sen University2
  2. First Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis ▼ from 6.1%

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Third Affiliated Hospital of Sun Yat-sen University1
  2. Sixth Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.2%Leads about 1 in 81 of China's research papers on Hirschsprung disease New since 2021

Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Sun Yat-sen University1
  2. Seventh Affiliated Hospital of Sun Yat-sen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
5.8%Leads about 1 in 17 of China's research papers on Leber hereditary optic neuropathy

Led 3 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Zhongshan Ophthalmic Center3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov